Company intelligence / Profile preview

Doctorpresso

Ownership: Private
Development stage: Commercial

Overview

Doctorpresso has developed and launched REDI, an AI-powered mobile application that uses voice analysis to detect early signs of depression. Clinical validation published in the Journal of Clinical Medicine demonstrated over 90% accuracy for detecting both minor and major depression using this technology. The app provides real-time analysis, privacy-focused on-device processing, and personalized recommendations based on cognitive behavioral therapy principles.

Therapeutic areas: Psychiatry
Modalities: DeviceMobile/smartphone appArtificial intelligence software (AI-based digital biomarker)
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

REDI

Commercial

Indications: Depression

Beyond the preview

Go deeper on Doctorpresso.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Doctorpresso.

Explore the full profile